News Archive

An article published today in the journal Nature brings us closer to understanding how differences in the genomes of individuals help contribute to common diseases and influence disease risk. Specifically, this study – by far the largest of its kind to date – revealed the effects of genetic variations on the levels of circulating blood proteins across thousands of individuals.

SomaLogic announced today that Melody Harris has joined SomaLogic as the company’s Chief Legal Officer. Ms. Harris comes to SomaLogic from Qualcomm Life, a digital health subsidiary of Qualcomm, where she led the legal, global privacy, and Quality, Regulatory & Compliance groups as Vice President & Chief Counsel.

SomaLogic has launched a new version of their proprietary SOMAscan® assay. This new version measures approximately 5,000 unique human protein analytes, almost four times more than its predecessor. The optimized assay format also uses new robotic instrumentation, removing as many manual interventions as possible.

SomaLogic announced today the establishment of a framework “Partnership for Personalized Health” with the Leeds Centre for Personalised Medicine and Health (CPMH), to be based in Leeds, UK. This collaboration – the first of its kind – aims to help individuals and professionals enhance health decisions by providing: accurate assessment of the current state and future disease risks, deeper understanding of causal and actionable factors that may drive these risks, and reliable monitoring of individuals to understand the effectiveness of interventions.

SomaLogic announced today that it has capped its $200 million funding round, anchored by iCarbonX with substantial investments from Nan Fung Life Sciences and Madryn Asset Management. The successful round will accelerate SomaLogic’s goal of becoming the world’s leading provider of precision digital health insights.

A new report published online in the American Heart Association journal Circulation describes the successful measurement of changes in blood proteins at a previously unattainable scale. The results revealed a large number of proteins that increased significantly soon after a heart attack—some that are well-known markers of myocardial damage but many that are completely new. This proof-of-principle study demonstrates that comprehensive protein profiling to diagnose and treat human health and disease is on the horizon.

The National Academy of Inventors (NAI) has named Larry Gold, the founder and chairman of the board of SomaLogic, as one of its 2017 fellows. Election to NAI Fellow status is the highest professional distinction given to academic inventors. NAI Fellows are inventors on U.S. patents and were nominated by their peers for their spirit of innovation and creation of new technologies that have significantly impacted society.

An international team of researchers has defined the series of immune system changes that occur when tuberculosis (TB) transitions from a non-infectious state to active disease.

An article published online in Scientific Reports shows that Down syndrome may be a form of chronic immune disorder. In the largest and most comprehensive study of its kind to date, investigators at the Crnic Institute for Down Syndrome, the Sie Center for Down Syndrome, the University of Colorado, and Somalogic measured the levels of over 3500 proteins in the blood of Down syndrome patients and compared them to non-Down syndrome controls.